在EGFR突变转移性转移性NSCLC的第一线和治疗序列:什么对哪个患者来说是正确的?
Pamela Abdayem1, Claudia Parisi1, David Planchard2,3
1Département de médecine oncologique, Gustave Roussy, 114 Edouard Vaillant Street, 94805, Villejuif Cedex, France.
Drugs
|January 31, 2026
概括
针对EGFR突变非小细胞肺癌 (NSCLC) 的第一线组合疗法在延缓抗性和大脑进展方面表现有前途. 用新型药物优化治疗序列是高级NSCLC患者的关键.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 使用表皮生长因子受体 (EGFR) 突变治疗非小细胞肺癌 (NSCLC) 的方法正在迅速发展.
- 经典的EGFR突变 (第19个外显子删除,第21个外显子L858R) 是NSCLC的一个重要子集.
- 目前的治疗策略正在根据最近的临床试验数据进行重新评估.
研究的目的:
- 审查EGFR突变NSCLC目前的治疗环境.
- 讨论最近的临床试验 (MARIPOSA,FLAURA 2) 对一线治疗策略的影响.
- 探索新兴的新药和治疗序列的重要性,预先治疗的患者.
主要方法:
- 对具有里程碑意义的临床试验的审查,包括MARIPOSA和FLAURA 2.
- 对结合疗法与单疗法相关数据的分析.
- 讨论新型治疗剂和预测生物标志物的讨论.
主要成果:
- 首线组合策略 (拉泽提尼布/阿米万塔马布,化疗/奥西默提尼布) 与奥西默提尼布单独治疗相比,具有延迟分子耐药性和内进展的潜力.
- 新型药物,如抗体-药物合物和双特异性抗体,为预先治疗的患者提供了新的选择.
- 患者和疾病特异性因素,包括中枢神经系统转移,对于选择一线治疗至关重要.
结论:
- 根据患者和疾病特征优化一线治疗选择至关重要.
- 包括新药在内的治疗方法的战略测序对于改善晚期EGFR突变NSCLC的结果至关重要.
- 对预测性生物标志物和生物标志物导向试验的进一步研究是必要的,以完善治疗策略.
相关概念视频
Mutations
94.5K
Overview
94.5K
Mutations
44.5K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.5K
Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Mutation, Gene Flow, and Genetic Drift
64.2K
In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.2K
Mutations in Microorganisms
724
Mutations are heritable changes in an organism’s genome involving alterations in the base sequence of DNA or RNA. These changes can influence cellular processes and phenotypic traits, potentially transforming the unaltered wild type into a mutant form. Such changes, termed forward mutations, are pivotal in shaping the genetic diversity of organisms.RNA viruses exhibit the highest mutation rates due to the absence of robust proofreading mechanisms during genome replication. In contrast,...
724
Point and Frameshift Mutations
1.2K
Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
1.2K


